

1 Dysfunctional neuro-muscular 2 mechanisms explain gradual gait 3 changes in prodromal spastic 4 paraplegia

5 **Christian Laßmann**^{1,2,3*,§}, **Winfried Ilg**^{2,4}, **Tim W. Rattay**^{5,6,7}, **Ludger Schöls**^{5,6,7},
6 **Martin Giese**^{2,4}, **Daniel F.B. Haeufle**^{1,4,8}

***For correspondence:**

christian.lassmann@uni-tuebingen.de (FMS)

Present address:[§]

Multi-level Modeling in Motor Control and Rehabilitation Robotics
Hertie Institute for Clinical Brain Research
Otfried-Müller-Str. 25
72076 Tübingen, Germany
Email: christian.lassmann@uni-tuebingen.de

7 ¹Multi-level Modeling in Motor Control and Rehabilitation Robotics, Hertie Institute for
8 Clinical Brain Research, University of Tübingen, Tübingen, Germany; ²Section
9 Computational Sensomotrics, Hertie Institute for Clinical Brain Research, Tübingen,
10 Germany; ³Department of Computer Engineering, Wilhelm-Schickard-Institute for
11 Computer Science, University of Tübingen, Tübingen, Germany; ⁴Centre for Integrative
12 Neuroscience (CIN), Tübingen, Germany; ⁵Department of Neurodegenerative Disease,
13 Hertie-Institute for Clinical Brain Research, and Center for Neurology, University of
14 Tübingen, Tübingen, Germany; ⁶German Center for Neurodegenerative Diseases
15 (DZNE), Tübingen, Germany; ⁷Center for rare diseases (ZSE) University of Tübingen,
16 Tübingen, Germany; ⁸Institute for Modeling and Simulation of Biomechanical Systems,
17 University of Stuttgart, Stuttgart, Germany

18
19 **Abstract** In Hereditary Spastic Paraplegia (HSP) type 4 (SPG4) a length-dependent axonal
20 degeneration in the cortico-spinal tract leads to progressing symptoms of hyperreflexia, muscle
21 weakness, and spasticity of lower extremities. Even before the manifestation of spastic gait, in
22 the prodromal phase, axonal degeneration leads to subtle gait changes. These gait changes –
23 depicted by digital gait recording – are related to disease severity in prodromal and
24 early-to-moderate manifest SPG4 subjects. We hypothesize that dysfunctional neuro-muscular
25 mechanisms such as hyperreflexia and muscle weakness explain these disease severity-related
26 gait changes of prodromal and early-to-moderate manifest SPG4 subjects. We test our
27 hypothesis in computer simulation with a neuro-muscular model of human walking. We
28 introduce neuro-muscular dysfunction by gradually increasing sensory-motor reflex sensitivity
29 based on increased velocity feedback and gradually increasing muscle weakness by reducing
30 maximum isometric force. By increasing hyperreflexia of plantarflexor and dorsiflexor muscles,
31 we found gradual muscular and kinematic changes in neuro-musculoskeletal simulations that are
32 comparable to subtle gait changes found in prodromal SPG4 subjects. Predicting kinematic
33 changes of prodromal and early-to-moderate manifest SPG4 subjects by gradual alterations of
34 sensory-motor reflex sensitivity allows us to link gait as a directly accessible performance marker
35 to emerging neuro-muscular changes for early therapeutic interventions.

37 Introduction

38 In many neurodegenerative movement disorders like Parkinson's disease, cerebellar ataxia, or
39 hereditary spastic paraplegia (HSP), gait impairments are among the leading symptoms. They of-
40 ten appear as the first signs (*Globas et al., 2008; Serrao et al., 2016; Ilg et al., 2016; Mirelman et al.,*
41 *2016*) and are one of the most disabling features in the progression of these diseases. Recently, it
42 has become possible to quantify specific subtle gait changes in early disease phases or even before
43 the manifestation of clinical disease symptoms (*Ilg et al., 2016; Mirelman et al., 2016*). The prodromal
44 phase of movement disorders (*Rattay et al., 2022*) attracts increasing research interest, as it
45 provides a promising window for early therapeutic intervention before substantially irreversible
46 neurodegeneration has occurred.

47 We have recently shown for hereditary spastic paraplegia type 4 (SPG4) subjects — the most
48 common autosomal dominant and pure motor form of HSP (*Rattay et al., 2022; Hazan et al., 1999*)
49 — that specific subtle changes in the kinematic gait pattern can be detected by quantitative move-
50 ment analysis in the prodromal phase, before the manifestation of spastic gait (*Lassmann et al.,*
51 *2022*). Changes that can be observed early are increased minimum plantarflexion or reduced foot
52 range of motion (RoM) which gradually increase in early manifest stages (*Lassmann et al., 2022*),
53 leading to gait patterns affecting the ankle, knee, and hip joints (*Martino et al., 2018, 2019; Piccinini*
54 *et al., 2011*). Especially the foot RoM and minimum plantarflexion show significant correlations to
55 disease severity already in prodromal and early manifest stages (*Lassmann et al., 2022*).

56 On the neuro-muscular level, key pathologies observed in HSP patients are hyperreflexia, leg
57 spasticity, and muscle weakness (*Fink, 2013*) caused by dying back axonopathy (*Rezende et al.,*
58 *2015; Lindig et al., 2015*). The origin of these pathologies is a length-dependent affection of the
59 cortico-spinal tract (*Harding, 1983; Fink, 2006*). Due to the length-dependency, early gait changes
60 have been primarily observed in the ankle joint (*Lassmann et al., 2022; Serrao et al., 2016*). Brisk
61 patellar and Achilles reflexes can be observed in clinical examinations already in the prodromal
62 phase (*Rattay et al., 2022*). In the manifest stage, additional spasticity and muscle weakness can
63 be observed in static conditions as well as in gait (*Marsden et al. (2012); Martino et al. (2019); Ri-*
64 *naldi et al. (2017)*). However, it is unknown to which part spastic hyperreflexia or muscle weakness
65 contribute to the subtle gait changes observed in prodromal and early phases.

66 In order to understand the emerging gait abnormalities in early disease stages, it is crucial
67 to investigate the development on the level of dysfunctional sensory-motor control mechanisms.
68 Forward-dynamic computer simulation with neuro-musculoskeletal models allows for investigat-
69 ing the effect of isolated sensory-motor alterations (*De Groote and Falisse, 2021*). This method
70 allows to reproduce healthy gait (*Geyer and Herr, 2010; Song and Geyer, 2015*) and to study the
71 contribution of individual sensory-motor reflexes to gait patterns (*van der Krogt et al., 2016; Haeu-*
72 *fle et al., 2018; Schreff et al., 2022; De Groote and Falisse, 2021*). The effect of neurodegenera-
73 tive dying back axonopathy, as seen in HSP, on gait can be investigated by gradual manipulation
74 of specific neuro-muscular mechanisms. Incremental bilateral plantarflexor weakness affecting
75 gait was previously investigated by *Waterval et al. (2021)*. *van der Krogt et al. (2010)* reproduced
76 gait characteristics of children with cerebral palsy by introducing a velocity-dependent stretch re-
77 flex, increasing muscle activity for the fast stretch of muscle fibers. *Jansen et al. (2014)* showed
78 how hyperexcitability of muscle spindle reflex loops contribute to hemiparetic gait by investigat-
79 ing length- and velocity feedback. *Bruel et al. (2022)* combine the effects of muscle weakness and
80 hyperreflexia to explain the sensory-motor origin of the spastic heel- and toe-walking. In their
81 study, they added muscle spindle-, length-, and force feedback to the two plantarflexor muscles,
82 Soleus (SOL) and Gastrocnemius medialis (GAS), and introduced muscle weakness by reducing the
83 maximum isometric muscle forces (*Bruel et al., 2022*).

84 In this study, we hypothesize that a gradual manipulation in sensory-motor reflex sensitivity and
85 muscle weakness can explain the emergence of early gait changes in prodromal subjects towards
86 early spastic gait in manifest SPG4 patients (see *Figure 1* for the study design). The gait of prodromal

87 mal subjects and manifest SPG4 patients had an intact gait cycle structure consisting of heel strike,
 88 roll-over, push-off and swing phases (here called: heel strike walking). We base our approach on
 89 a previously published model predicting healthy human gait kinematics and dynamics (*Geyer and*
 90 *Herr, 2010*). In this model, we gradually manipulate hyperreflexia based on muscle spindle veloc-
 91 ity feedback and muscle weakness to determine whether a singular neuro-muscular dysfunction
 92 or only their combination can explain the gradual kinematic changes observed in experimental
 93 data. We expect that developing gait changes over disease severity of prodromal subjects to the
 94 spastic gait of mild-to-moderate manifest patients can be predicted by altering plantarflexor and
 95 dorsiflexor muscle spindle reflex sensitivity and leg muscle weakness, caused by length-dependent
 96 axonal degeneration in SPG4.




Figure 1. We first used data of an instrumented gait analysis to investigate gait changes of healthy controls (green), prodromal SPG4 (blue), and manifest SPG4 (red) patients. We identified characteristic changes for the three different groups, which were recently published (*Lassmann et al., 2022*). Secondly, we introduced and gradually manipulated neuro-muscular mechanisms, i.e. hyperreflexia (muscle spindle velocity feedback, orange), muscle weakness (reduced isometric force, light blue), and their combination in a neuro-musculoskeletal model and expected to predict relative gait changes, as in experimental data.

97 Methods and Materials

98 Experimental Data

99 We evaluate data from our previously published study (*Lassmann et al., 2022*), which included 17
 100 manifest SPG4 patients, 30 prodromal SPG4, and 23 healthy control participants. The study was
 101 conducted according to the Helsinki Declaration and approved by the Institutional Review Board
 102 of the University of Tübingen (reference number: 266/2017BO2) for the preSPG4 Study. In addi-
 103 tion, written informed consent was obtained from all study participants. Subjects were instructed
 104 to walk normally in a self-determined pace. All participants had an intact gait cycle structure con-
 105 sisting of heel strike, roll-over, push-off and swing phases (here called: heel strike walking). Partic-
 106 ipants underwent an instrumented gait analysis in a movement laboratory using an infrared-
 107 camera-based motion capture system (VICON FX with ten cameras). Gait cycles were recorded
 108 with 41 reflecting markers at a sampling rate of 120 Hz, and extracted by detection of the heel
 109 strike event. Trials were smoothed by a Savitzky-Golay polynomial filter and resampled equidis-
 110 tantly to 100 data points per gait cycle. For the analysis, we calculated stride length, gait speed and
 111 joint angles, to compare to simulated data.

112 **Computational model of human gait**

113 We used a neuro-musculo-skeletal model of human gait, as it was used recently by *Bruel et al.*
114 (2022). The model is planar (sagittal plane) with seven segments (trunk-pelvis, bilateral thigh, lower-
115 leg, and foot) and seven degrees of freedom (simplified from OpenSim gait2392 (*Delp et al., 2007*)).
116 The planar model was used, since the most prominent differences between healthy controls, pro-
117 dromal SPG4, and manifest SPG4 patients were found in the flexion and extension angles espe-
118 cially in the foot segment (*Lassmann et al., 2022*). We modeled seven Hill-type muscles (Millard-
119 equilibrium muscle model (*Millard et al., 2013*)), namely Gluteus maximus (GLU), Iliopsoas (IL), Rec-
120 tus femoris (RECT), Vastus intermedius (VAS), Gastrocnemius medialis (GAS), Soleus (SOL), and Tibil-
121 ias anterior (TA) per leg. Muscle path, optimal fiber length, pennation angle, tendon slack length,
122 and maximum isometric forces were set to the values in the Gait2392 model. Ground contact was
123 modeled using two viscoelastic Hunt-Crossley contact spheres on each foot, serving as heel and
124 toe contacts.

125 The neuronal control model calculated muscle stimulation signals U for each of the fourteen
126 muscles according to a gait state-dependent reflex-based controller based on *Geyer and Herr*
127 (2010). The controller considered muscle force and length feedback, vestibular feedback, and con-
128 stant signals to generate muscle excitation. Reflex gains could differ between five gait phases (early
129 stance, late stance, lift-off, swing, and landing), as proposed in previous studies (*Song and Geyer,*
130 *2015; Ong et al., 2019; Waterval et al., 2021*).

131 **Simulation study design: a model of spastic hyperreflexia and muscle weakness**

132 This study systematically introduced sensory-motor alterations to model healthy, prodromal and
133 early-to-moderate manifest gait in SPG4. The study design has two axes. On the first axis, we inves-
134 tigated three different control scenarios: spastic hyperreflexia, muscle weakness, and a combina-
135 tion of both. On the second axis, we investigated the magnitude of the respective sensory-motor
136 alterations.

137 **First axis:** To model spastic **hyperreflexia**, we introduced a gain parameter $\omega_h \in [0\%...100\%]$.
138 ω_h is multiplied by the equation calculating the muscle spindle velocity feedback:

$$U_V = \omega_h \cdot K_V \cdot (V - V_0) \quad (1)$$

139 with V and V_0 being the normalized CE velocity ($(L/L_{opt})/s$) and the respective constant reference
140 velocity. $K_V = 0.12 s$ is the velocity feedback gain which did not lead to a walking gait in our opti-
141 mization approach in an exploratory examination. $\omega_h = 0\%$ results in a deactivated velocity reflex
142 and $\omega_h = 100\%$ results in the maximally investigated velocity reflex sensitivity (hyperreflexia). ω_h
143 was added to the ankle plantarflexors GAS and SOL, and ankle dorsiflexor TA during the stance
144 and swing phase.

145 To model **muscle weakness**, we introduced a gain parameter $\omega_w \in [0\%...100\%]$ which directly
146 reduces the maximum isometric muscle force (F_{max}) of the leg muscles. $\omega_w = 0\%$ represents a
147 model with all muscles at full strength, while $\omega_w = 100\%$ represents a reduction of the isometric
148 force to levels reported by *Marsden et al. (2012)*, namely 42% of dorsiflexors, 58% of plantarflexors,
149 62% knee extensors, 65% knee flexors, 89% hip extensors, and 70% hip flexors.

150 To model the third scenario, we combined both approaches to investigate the interplay of both
151 symptoms. For this, we introduced the parameter ω_{hw} , which sets both, velocity feedback gain
152 $\omega_h = \omega_{hw}$ and muscle weakness $\omega_w = \omega_{hw}$ simultaneously.

153 **Second axis:** To investigate gradual sensory-motor alterations, the magnitude of the gains was
154 increased in 15 steps: $\omega_h, \omega_w, \omega_{hw} = [0\%, 6.67\%, 13.34\%, 20\%, \dots, 100\%]$. Low ω -values mean minimal
155 sensory-motor alterations, i.e., low hyperreflexia and muscle weakness, while ω -values of 100%
156 represent the highest alterations investigated in this study. See Supplementary Figure 1 for details
157 on the gradual change of velocity feedback gain and muscle weakness and their combination.

158 Optimization of controller parameters

159 For each of the scenarios described above, all other controller parameters were optimized. These
 160 are the feedback gains of the other reflexes (length, force, and vestibular) within each state, transi-
 161 tion thresholds between the phases, and the initial joint angles. We used the open-source software
 162 SCONE with Hyfydy for the optimization, a dedicated software to run and optimize predictive neuro-
 163 muscular simulations *Geijtenbeek (2019, 2021)*. The cost function for the optimization (see *Equa-
 164 tion 2*) considered a minimum gait speed *Equation 3*, an effort measure from *Wang et al. (2012)*
 165 minimizing metabolic energy expenditure of muscles (J_{effort}), a joint measure penalizing hyperex-
 166 tension and -flexion of the ankle (*Equation 4*) and knee (*Equation 5*) joints, and ground reaction
 167 force measure penalizing high forces during gait (J_{grf}):

168

$$J_{\text{cost}} = 100 * J_{\text{gait}} + 0.1 * J_{\text{effort}} + 0.1 * J_{\text{ankle joint}} + 0.01 * J_{\text{knee joint}} + 10 * J_{\text{grf}} \quad (2)$$

$$J_{\text{gait}} = \begin{cases} 1, & \text{if COM height} < 0.85 * \text{initial COM height} \\ \frac{\text{gait speed}}{1 \frac{m}{s}}, & \text{if gait speed} < \text{minimum gait speed} \\ 0, & \text{else} \end{cases} \quad (3)$$

$$J_{\text{ankle joint}} = \begin{cases} 0, & \text{if } -60^\circ < \text{ankle angle} < 60^\circ \\ (|\text{ankle angle} - 60|)^2, & \text{else} \end{cases} \quad (4)$$

$$J_{\text{knee joint}} = \begin{cases} 0, & \text{if knee angle moment} > -5\text{Nm} \\ |\text{knee angle moment}|, & \text{else} \end{cases} \quad (5)$$

$$J_{\text{grf}} = \begin{cases} \left| \frac{\text{GRF}}{\text{Body weight}} \right| - 1.5 * \text{Body weight}, & \text{if GRF} > 1.5 * \text{Body weight and time} > 1\text{s} \\ 0, & \text{else} \end{cases} \quad (6)$$

169 SCONE uses the Covariance Matrix Adaptation Evolutionary Strategy from *Igel et al. (2006)*. The
 170 optimization was stopped when the average reduction of the cost function score was less than
 171 0.0001% compared to the previous iteration. We simulated gait for 30 seconds, always starting
 172 from the same initial parameters. We only considered simulations with stable walking until the
 173 simulation ends. For analysis we excluded the first gait cycle, resampled to 100 data points per
 174 gait cycle, and averaged over all gait cycles.

175 Data evaluation

176 We compared the simulation output to the experimental data for specific relevant gait features
 177 identified in our previous study *Lassmann et al. (2022)*. As gradually altering features in prodromal
 178 and manifest SPG4, we identified the minimum plantarflexion, the foot range of motion (RoM),
 179 and the maximum ground clearance of the heel. For manifest SPG4 the knee angle at heel strike
 180 increased and the maximum heel angle and knee RoM reduced significantly. Furthermore, gait
 181 speed and stride length were reduced over disease progression for manifest SPG4 patients *Lass-
 182 mann et al. (2022)*. Hip, knee, and ankle joint angle kinematics during the gait cycle were compared
 183 between healthy controls, prodromal SPG4 subjects, and manifest SPG4 patients. We compared
 184 the simulation results with nine key features of the experimental data: (1) ankle RoM, (2) minimum
 185 plantarflexion (swing phase), (3) ankle angle at heel strike, (4) ankle angle at maximum heel ground
 186 clearance, (5) knee RoM, (6) maximum knee angle, (7) knee angle at heel strike, (8) gait speed, and
 187 (9) stride length. Peak and average muscle activation for SOL, GAS, and TA was calculated for each

188 gait phase (early stance, late stance, lift-off, swing, and landing). SOL and TA co-activation values
189 were calculated with average muscle activation values for each of the five gait phases:

$$CA_{\text{phase}} = \begin{cases} \frac{\text{sol} + \text{ta}}{2} * \frac{\text{sol}}{\text{ta}}, & \text{if } \text{sol} < \text{ta} \\ \frac{\text{ta} + \text{sol}}{2} * \frac{\text{ta}}{\text{sol}}, & \text{if } \text{ta} < \text{sol} \end{cases} \quad (7)$$

190 where sol and ta represent the mean muscle activation for a certain gait phase. For statistical
191 comparison Kruskal-Wallis test and post hoc Dunn's test for multiple group comparisons were used.
192 We report statistical significance as *: $p < 0.05$, **: $p < 0.0056$ (Bonferroni corrected with 9 feature
193 comparisons), and ***: $p < 0.001$.

194 We used the SPRS score (*Schüle et al., 2006*) to categorize subjects into clinical disease severity and
195 find possible explanations by increasing velocity feedback gains in the simulations.

196 Spearman's ρ was used to identify significant correlations of increased muscle spindle velocity
197 feedback and increased muscle weakness for the nine gait features and optimization parameters,
198 e.g., force feedback gains of individual muscles and metabolic energy expenditure (*Wang et al.,*
199 *2012*).

200 Results

201 Experimental gait data

202 As recently published, instrumental gait analysis revealed significant group differences between
203 healthy controls (HC), prodromal SPG4 subjects, and manifest SPG4 patients (*Lassmann et al.,*
204 *2022*). All participants performed a self-determined heel strike walking. For this study, we extracted
205 joint angle kinematics and other gait parameters, as described in detail by *Lassmann et al. (2022)*.

206 Several gait parameters showed significant differences between healthy controls and prodromal
207 SPG4 with increasing effects in manifest SPG4 patients. Minimum plantarflexion ($p = 0.029^*$),
208 and ankle angle at maximum heel ground clearance ($p = 0.029^*$) were significantly increased for
209 prodromal SPG4 and manifest ($p < 0.001^{***}$) in comparison to healthy controls. Pearson's ρ
210 showed a gradual increase of these features with disease severity ($\rho = 0.48$, $p < 0.001^{***}$; $\rho = 0.5$,
211 $p < 0.001^{***}$, respectively). For manifest SPG4 patients, the ankle and knee RoM ($p < 0.001^{***}$) and
212 maximum knee angle ($p = 0.013^*$) were significantly reduced, and the knee angle at heel strike was
213 increased ($p < 0.001^{***}$). The gait speed and stride length were decreased for manifest SPG4, but
214 not for prodromal SPG4 subjects. **Table 1** shows mean values and standard deviation for all nine
215 analyzed features of the three groups.

216 Kinematics of the ankle, knee, and hip joint during the gait cycle showed differences between
217 HC (green), prodromal SPG4 (blue), and manifest SPG4 (red in *Figure 2a-c*). The most prominent
218 differences occurred during the swing phase, e.g., the increasing minimum plantarflexion angle
219 from healthy controls to prodromal subjects and manifest SPG4 patients (*Figure 2a* at around 70%
220 of the gait cycle), indicating a progression with disease severity. Furthermore, the increased knee
221 angle at heel strike in the manifest group is visible (*Figure 2b*, the beginning of the gait cycle).

222 Neuro-musculoskeletal gait model


223 Simulated healthy walking pattern

224 The simulation of the not adapted *Geyer and Herr (2010)* controller can reproduce healthy gait.
225 *Figure 2d-f* in black ($\omega = 0\%$) and **Table 1** show the results for the model with optimized controller
226 parameters (optimized in Scone). We found reduced maximum ankle dorsiflexion and a more
227 extended swing phase compared to our experimental data.

228 Effect of increasing velocity feedback gain

229 With increasing levels of velocity feedback gain K_V (ω_h) to plantarflexor and dorsiflexor muscles
230 during the stance and swing phase, several kinematic changes occurred within heel strike walking.

Experimental kinematics



Simulated kinematics




Figure 2. a-c: mean flexion and extension angles of ankle, knee, and hip joints over the gait cycle in percent for healthy controls (green), prodromal SPG4 (blue), and manifest SPG4 (red), with their standard deviation. Significant periods are indicated as lines above the trajectory plots indicating different levels of significance (thin line: $p < 0.05$, intermediate line: $p < 0.0056$, and bold line: $p < 0.001$). Differences between prodromal SPG4 vs. HC and manifest SPG4 vs. HC are shown as blue and red lines, respectively. d-f: flexion and extension angles of ankle, knee, and hip joints over the gait cycle in percent for different levels of velocity feedback gains (color coded from black: $\omega_h = 0\%$, light grey: $\omega_h = 93\%$) of plantarflexor and dorsiflexor muscles. The extracted features are highlighted yellow, namely the minimum plantarflexion (d) and knee angle at heel strike (e).

231 **Ankle:** The minimum plantarflexion angle reduced from -17.3° ($\omega_h = 0\%$) to -11.4° at $\omega_h = 20\%$ and
 232 further to -8.35° ($\omega_h = 40\%$) and -4.8° ($\omega_h = 93\%$) (see **Figure 2d**). This resulted in a strong correla-
 233 tion between increasing velocity feedback gains and minimum plantarflexion ($\rho=0.9$, $p<0.001^{***}$,
 234 compare **Figure 3a**). In addition, also the ankle angle at heel strike was gradually increased ($\rho=-$
 235 0.87 , $p<0.001^{***}$) and gait speed was reduced ($\rho=-0.53$, $p=0.04^*$). **Knee:** At heel strike, the knee
 236 angle was gradually increased from $\omega_h \geq 53\%$ to $\omega_h = 93\%$ ($\rho=0.88$, $p<0.001^{***}$, compare **Fig-**
 237 **ure 2e** and **Figure 3b**). For comparison with experimental data, the results of different iterations of
 238 increasing velocity feedback gain are shown in **Table 1** and all results with correlations in Supple-
 239 mentary Table 1.

240 SOL average activation was increased during the early stance phase ($\rho=0.95$, $p<0.001$) and re-
 241 duced during lift-off ($\rho=-0.75$, $p=0.0012$) Supplementary Figure 2a. During landing, there was a
 242 greater SOL activation ($\rho=0.84$, $p<0.001$). For GAS, the average activation during the early stance
 243 phase was increased with increasing ω_h , showing a prolonged GAS activation over the stance phase;
 244 however, with a shortened peak muscle activation period Supplementary Figure 2b. During the
 245 landing phase, the GAS average activation increased with higher velocity feedback gain ($\rho=0.97$,
 246 $p<0.001$). Tibialis anterior (TA) peak activation increased at early stance ($\rho=0.87$, $p<0.001$) Sup-
 247plementary Figure 2c. During swing and landing, TA activity increased with ω_h ($\rho=0.68$, $p=0.0057$;
 248 $\rho=0.94$, $p<0.001$, respectively) Supplementary Figure 2c. SOL-TA co-activation increased during
 249 early stance ($\rho=0.87$, $p<0.001$), swing ($\rho=0.68$, $p=0.0057$), and landing ($\rho=0.93$, $p<0.001$), and
 250 decreased during lift-off ($\rho=-0.63$, $p=0.013$) with increasing ω_h .

251 All iterations with increasing muscle spindle velocity feedback gain, except for $\omega_h = 100\%$, could
 252 be optimized to a stable walking simulation.




Figure 3. Increasing levels of velocity feedback gain (orange), muscle weakness (light blue), and velocity feedback gain + muscle weakness (purple) with simulation iteration $\omega = 0\%$ to $\omega = 100\%$ and linear fits. a) minimum plantarflexion and b) knee angle at heel strike are shown with significant pearson correlation coefficients. Asterisks indicate significant levels of *: $p<0.05$, **: $p<0.0056$, and ***: $p<0.001$. For $\omega_h = 100\%$ and $\omega_{hw} > 60\%$ optimization led to no stable walking simulations.

253 Effect of increasing muscle weakness

254 The gradual increase of muscle weakness $F_{\max}(\omega_w)$ as reported in **Marsden et al. (2012)** resulted in
 255 an increased ankle angle at heel strike ($\rho=0.8$, $p<0.001^{***}$, compare **Figure 3a**). The maximum
 256 knee angle differed between simulation scenarios in a range of 52° ($\omega_w = 20\%$) and 75° ($\omega_w =$
 257 66.7%), with no significant correlation over increased muscle weakness. Other investigated features
 258 did not show a specific pattern with increasing muscle weakness. All simulations with increasing

259 muscle weakness ($\omega_w = 0\% \dots 100\%$) could be optimized to a stable heel strike walking simulation.
260 For all simulation results, see Supplementary Table 2 and Supplementary Figure 3.

261 Combined velocity feedback gain and muscle weakness

262 The combination of a gradual increase of velocity feedback gain and muscle weakness (ω_{hw}) re-
263 sulted in patterns similar to the velocity feedback gain scenario. During the swing phase, the min-
264 imum plantarflexion was reduced for higher ω_{hw} ($\rho=0.96, p<0.001^{***}$, see **Figure 3a**). The ankle
265 angle reduced at heel strike ($\rho=-0.96, p<0.001^{***}$) and increased at maximum heel ground clear-
266 ance ($\rho=0.98, p<0.001^{***}$). The knee angle at heel strike increased with ω_{hw} ($\rho=0.76, p=0.011^*$,
267 see **Figure 3b**). Gait speed and stride length were reduced to comparable levels as in the velocity
268 feedback gain scenario, however, with no significant correlation to increased ω_{hw} (see Supplemen-
269 tary Table 3 and Supplementary Figure 4). The optimizer failed to produce stable heel strike walking
270 with $\omega_{hw} \geq 60\%$, showing a reinforced effect by combining the gradually increased velocity feedback
271 gain and muscle weakness. At $\omega_{hw} = 73\%$ the optimization dismissed the heel strike walking but
272 produced a stable toe-walking pattern with initial ball contact, increased hip flexion angle and a
273 time offset at maximum knee flexion angle (compare Supplementary Figure 5).

274 Optimized control parameters and cost terms

275 For each specified velocity feedback gain and/or muscle weakness parameters (ω_h , ω_w , or ω_{hw}),
276 we optimized all other controller parameters to find a suitable gait minimizing our locomotion
277 cost function (**Equation 2**). This re-optimization resulted in changes in the cost terms and the
278 controller parameters and reflected the possibility of the rest of the nervous system adapting to
279 specific sensory-motor changes. For increasing velocity feedback gain and combined velocity feed-
280 back gain and muscle weakness, the cost term J_{effort} metabolic energy expenditure (**Wang et al.,**
281 **2012**) increased with increasing ω (ω_h : $\rho = 0.79, p < 0.001^{***}$; ω_{hw} : $\rho = 0.66, p = 0.038^*$, re-
282 spectively). The controller parameter *length feedback gain* of TA (optimized over the whole gait
283 cycle) increased with higher velocity feedback gains ($\rho = 0.72, p = 0.002^{**}$). The *force feedback*
284 *gains* of SOL and GAS during lift-off and swing phases decreased with higher velocity feedback
285 gains ($\rho = -0.94, p < 0.001^{***}$, for both) and combined velocity feedback and muscle weakness
286 ($\rho_{\text{SOL}} = -0.98, p_{\text{SOL}} < 0.001^{***}$; $\rho_{\text{GAS}} = -0.99, p_{\text{GAS}} < 0.001^{***}$). For the combined controller of
287 muscle weakness and velocity feedback gain, the offset of TA muscle spindle length feedback (L_0)
288 was optimized to an increased value of 1.07 (as a fraction of the optimal TA muscle fiber length
289 of 9.8cm) for the toe-gait scenario ($\omega_{hw} = 73\%$), in comparison: for all other combined controller
290 scenarios ($L_0(\omega_{hw} \in [6.67\% \dots 60\%]) = 0.65 \pm 0.003$). This offset leads to a reduced TA activation during
291 stance, lift-off, and landing Supplementary Figure 6. For more details on the optimized parameters,
292 see Supplementary Table 4.

293 Discussion

294 We hypothesized, that the subtle gait changes in heel strike walking observed in prodromal SPG4
295 subjects could be explained by gradual changes in neuro-muscular feedback mechanisms. To in-
296 vestigate this, we implemented gradually increased sensitivity of sensory-motor reflex in a neuro-
297 musculoskeletal forward simulation of heel strike walking (**Geyer and Herr, 2010**). Increasing levels
298 of velocity feedback gain in plantarflexor and dorsiflexor muscles resulted in kinematic and muscu-
299 lar changes comparable to those observed in prodromal subjects and early-to-moderate manifest
300 SPG4 patients.

301 Increasing hyperreflexia explains the development of early gait changes in SPG4

302 On the kinematic level, the earliest gait changes in prodromal SPG4 subjects occur in the foot
303 segment and ankle joint (**Lassmann et al., 2022**). Increasing muscle spindle velocity feedback (ω_h)
304 in the simulation caused several gait changes that are in line with kinematic changes of heel strike
305 walking in prodromal subjects and early-to-moderate manifest SPG4 patients.

Gait feature	HC	prod SPG4	man SPG4	$\omega_h = 0\%$	$\omega_h = 20\%$	$\omega_h = 40\%$	$\omega_h = 60\%$	$\omega_h = 80\%$	$\omega_h = 93\%$
ankle RoM	33.7 ± 8.5	31.5 ± 8.3	25.2 ± 6.9 ***	25.4	19	16.2	15.7	15.1	13.7
min Plantarflexion	-20.8 ± 9.5	-13.4 ± 10.5 *	-8.5 ± 7.9 ***	-17.3	-11.4	-8.4	-6.2	-7.3	-4.8
ankle at HS	1.1 ± 7.2	5 ± 9.3	4.7 ± 6.3	4	1.3	-0.5	-1.1	-4.4	-0.7
ankle at max HGC	-18.6 ± 8.7	-11.3 ± 10.6 *	-6.7 ± 8.5 ***	-14.7	-8.1	-5.1	-3.3	-3.5	-2.3
knee RoM	60.2 ± 4.9	58.2 ± 6.3	47.1 ± 11.3 ***	61	61.7	61.9	62.2	63	65.5
knee max angle	57.7 ± 7.9	57 ± 7.2	47 ± 12.6 *	62.3	63	63.4	62.7	63.9	67.1
knee at HS	0.8 ± 6.8	2.8 ± 5.7	11.9 ± 7.9 ***	2.0	1.9	3.8	11.5	4.3	10.2
gait speed [m/s]	1.36 ± 0.1	1.28 ± 0.1	1.09 ± 0.2 ***	1.2	1.16	1.05	1.08	1.03	1.06
stride length [cm]	146 ± 90	137 ± 11	116 ± 19 ***	148	144	1.35	1.39	1.32	1.33

Table 1. Mean results for gait features with standard deviation (STD) for experimental and simulated data. RoM ≡ Range of Motion, PF ≡ Plantarflexion, HS ≡ Heel strike, HGC ≡ Heel ground clearance. Asterisks indicate significance: * if $p < 0.05$ and ** if $p < 0.001$ in comparison to HC. Different levels of the velocity feedback gain scenario (ω_h) are given for comparison.

306 In the simulation, the minimum plantarflexion increased gradually with ω_h ($\rho=0.9$, $p<0.001$)
307 to comparable levels as it increased over disease severity, measured by the SPRS score (*Schüle*
308 *et al., 2006*), in the experimental data of prodromal and early-to-moderate manifest SPG4 subjects
309 ($\rho=0.49$, $p<0.001$). With $\omega_h \geq 53\%$ the minimum plantarflexion saturates, as it has been shown in
310 *Lassmann et al. (2022)* for early-to-moderate manifest SPG4 patients.

311 The ankle RoM was identified as key feature of kinematic changes in prodromal and manifest
312 SPG4 subjects (*Lassmann et al., 2022*) and used to cluster manifest HSP patients into severity-
313 related groups (*Serrao et al., 2016*). In the simulation, the ankle RoM reduced gradually with
314 increasing ω_h ($\rho=-0.99$, $p<0.001$), as in the experimental data with disease severity ($\rho=-0.5$,
315 $p<0.001$). However, the absolute values did not fit the experimental data due to reduced maxi-
316 mum dorsiflexion in all simulations.

317 Comparable to the experimental data with disease severity ($\rho=0.48$, $p<0.001$), the knee angle
318 at heel strike was gradually increased with greater velocity feedback gain ($\rho=0.88$, $p<0.001$). For
319 low velocity feedback gains ($\omega_h < 53\%$), the knee angle at heel strike remained on a constant level
320 comparable to healthy controls and prodromal SPG4 subjects. With greater velocity feedback gains,
321 the knee angle at heel strike increased, matching the kinematic changes in manifest SPG4 patients.




Figure 4. a: Minimum plantarflexion and b: knee angle at heel strike of experimental data and simulations over disease severity (SPRS score) and velocity feedback gain ω_h . The three experimental groups are color-coded with healthy controls (green), prodromal SPG4 (blue), and manifest SPG4 (red). Shown are averaged values for SPRS scores as blue and red circles. Error bars are showing distributions of all groups with their mean SPRS score (position on lower x-axis) and standard deviation of SPRS score indicated by horizontal error bars. Orange squares are showing simulation data at different gains of velocity feedback (ω_h , upper x-axis). Quadratic fit for simulations with increasing velocity feedback gain is shown in the respective color.

322 Currently, there is no measurement or biomarker linking our velocity feedback gain parameter
323 ω_h to disease severity. However, when plotting kinematic features like minimum plantarflexion
324 and knee angle at heel strike of experimental data over SPRS score, which indicates disease sever-
325 ity (*Schüle et al., 2006*), and of simulated data over sensory-motor reflex sensitivity ω_h , the plot
326 suggests reproducing the gradually changing gait features of prodromal and early-to-moderate
327 manifest SPG4 subjects with disease severity (see *Figure 4*). These findings allow us to conclude
328 that velocity-dependent hyperreflexia can explain the development of earliest gait changes in pro-
329 dromal subjects and early spastic gait in patients with hereditary spastic paraplegia type 4 and
330 shows the importance of gait as directly accessible performance marker for early therapeutic in-
331 terventions.

332 **Increasing hyperreflexia predicts changes in muscular coordination**

333 The increasing velocity feedback gain ω_h has consequences beyond the kinematic changes. Opti-
334 mizing all other neuronal control parameters for any given ω_h , increased SOL and TA activity during
335 the early stance and swing phase, with a higher level of co-activation during early stance and swing
336 phase. *Rinaldi et al. (2017)* reported a similarly increased co-activation of antagonist ankle muscles
337 (SOL-TA) during the stance and swing phase in manifest HSP patients. *Martino et al. (2019)* found
338 a prolonged activation of ankle plantarflexor muscles in manifest HSP, which could be replicated
339 in our simulated GAS activation, however, with a shorter peak period.

340 Our simulations' metabolic energy expenditure (*Wang et al., 2012*) was positively correlated
341 with increasing velocity feedback gains. This result is in line with *Rinaldi et al. (2017)*, who report
342 an increase in energetic consumption in manifest HSP patients.

343 These findings indicate that the increased velocity feedback gain, a model representation of hy-
344 perreflexia in the ankle joint muscles, predicts not only kinematic but also muscular and energetic
345 trends observed in prodromal and early-to-moderate manifest SPG4 patients.

346 **Severely spastic gait in manifest SPG4**

347 In contrast to other simulation studies that focus on severe manifest spastic gait with altered gait
348 patterns, we investigated the prodromal and early phases of spastic gait with an intact gait cycle
349 structure consisting of heel strike, roll-over, push-off, and swing phases (here called: heel strike
350 walking).

351 We did not find the kinematic changes occurring in prodromal and early-to-moderate manifest
352 SPG4 subjects for increasing muscle weakness. However, the combined effects of hyperreflexia
353 and muscle weakness ω_{hw} show the importance of muscle weakness in manifest hereditary spastic
354 paraplegia. By simultaneously increasing both velocity feedback gain and muscle weakness, we
355 found a toe-gait pattern Supplementary Figure 5, which is characteristic of later manifest stages
356 of hereditary spastic paraplegia. Our results suggest a decrease of TA activation in the toe-gait
357 scenario, resulting in a decrease of TA-SOL reciprocal inhibition. In combination with the increased
358 plantarflexor velocity feedback gain, this leads to an over-activity of plantarflexor muscles during
359 the stance and swing phase.

360 Other simulation studies previously investigated severe manifest gait in different movement
361 disorders by introducing hyperreflexia and muscle weakness. *Waternal et al. (2021)* simulated bi-
362 lateral plantarflexor weakness by incrementally introducing GAS and SOL muscle weakness. They
363 report that gait altered meaningfully when maximum isometric muscle force was reduced to less
364 than 40%. In our study, we reduced muscle force to levels found by *Marsden et al. (2012)*, with a
365 minimum muscle force of 42% occurring in dorsiflexors. We found no exclusive effect of the inves-
366 tigated muscle weakness on pathological gait in SPG4 patients, which might be explained by the
367 still remaining isometric force of more than 40%. *Bruel et al. (2022)* showed that increased velocity-
368 and force-related sensory-motor reflexes of GAS and SOL lead to pathological toe-walking patterns,
369 which can be seen in later stages of manifest spastic patients. Furthermore, *Jansen et al. (2014)*
370 used hyper-excitability of muscle spindle length- and velocity reflex loops to simulate hemiparetic
371 gait in a neuro-musculoskeletal model. They found that both feedback mechanisms introduced to
372 SOL, GAS, Vastus (VAS), and Rectus femoris (RECT), can lead to specific gait impairments, such as
373 reduction of ankle dorsiflexion and decreased knee flexion during stance.

374 **Study limitations**

375 In the combined sensory-motor reflex scenario of increased velocity feedback gain and muscle
376 weakness, we assumed a simultaneous linear development of both factors from 0% to 100%. The
377 experimental results of *Rattay et al. (2022)* suggest that lower leg spasticity and muscle weakness
378 emerge contiguously, but later than hyperreflexia, which was found in almost all prodromal SPG4
379 subjects (*Rattay et al., 2022; Lassmann et al., 2022*). For higher ω_{hw} in the combined scenario,
380 several optimizations did not find a stable walking gait. Further investigations in the longitudinal

381 development of muscle weakness and hyperexcitability of muscle spindle reflex loops in SPG4
382 patients are necessary to understand the interplay of these symptoms.

383 The cost function for the parameter optimization determines the resulting gait pattern. For our
384 simulations, we used a combined cost function that penalized excessive ground reaction forces, as
385 suggested by *Veerkamp et al. (2021)*. Furthermore, the minimum gait speed was set to 1 m/s, which
386 is the average gait speed of our early-to-moderate SPG4 group (*Lassmann et al., 2022*). Hyper-
387 extension and -flexion of ankle and knee joints were penalized to ensure normal gait patterns. We
388 introduced this cost function, since we were interested in the subtle gait changes of prodromal
389 and early-to-moderate SPG4 subjects, who still perform a heel strike walking pattern. To simulate
390 more severe stages of SPG4, a different cost function may be needed, to allow a less constrained
391 gait pattern (*Bruel et al., 2022*).

392 The length-dependent axonal degeneration in the cortico-spinal tract of SPG4 patients (*Fink,*
393 *2006*) suggests that spinal reflex changes may emerge first for distal reflex loops. For this reason,
394 we studied gradual velocity feedback gains only at the most distal muscles (GAS, SOL, and TA). Also
395 *Martino et al. (2019)* found altered muscle activation in the most distal muscles. For muscle weak-
396 ness, we considered an affection of all simulated muscles, as reported in *Marsden et al. (2012)*.
397 Altering the sensory-motor reflex sensitivity in more proximal muscles may increase the simula-
398 tion prediction accuracy of kinematic changes also in the other joints – at the cost of interpretation
399 complexity. Nevertheless, it is crucial to investigate further the impact of muscle activation and
400 hyperexcitability of the knee and hip muscle reflex loops, e.g., as *Di Russo et al. (2021)* did to inves-
401 tigate the effect of different sensory-motor reflex sensitivities on gait speed and stride length.

402 The model we used is limited to simulating walking in the sagittal plane (two-dimensional). In
403 severe manifest SPG4 patients, hip adductor spasticity is a common symptom (*Van Lith et al., 2019*)
404 and leads to instability. Simulating the 3D gait pattern of SPG4 patients would be needed to include
405 a more detailed symptomatic pattern of muscle spasticity and weakness.

406 **Conclusion and outlook**

407 Very early kinematic changes in the gait pattern present a directly accessible performance measure
408 for prodromal and manifest SPG4 subjects *Lassmann et al. (2022)*. We here identified sensory-
409 motor reflex sensitivity changes as a possible explanation for these subtle kinematic changes. In
410 our model, the gradual increase of reflex sensitivity can explain the gradual change in heel strike
411 walking observed with increasing disease severity. On the other hand, muscle weakness could be
412 compensated by other adapting spinal reflexes and did not lead to the observed kinematic changes.
413 From this, we speculate that early pharmacological interventions to reduce spasticity (e.g., by ba-
414 clufen) might reduce subtle gait changes by reducing the sensory-motor reflex sensitivity. However,
415 the side-effects of increased muscle weakness may be compensated intraindividual through adapt-
416 ing spinal reflexes. This thought experiment indicates that pharmacological reduction of spasticity
417 in early SPG4 patients could delay the onset of manifest spastic gait. In the currently running longi-
418 tudinal experimental study (*Rattay et al., 2022; Lassmann et al., 2022*), we will further investigate
419 individual kinematic changes over time and simulate the development of sensory-motor reflex al-
420 terations to link gait changes to neuro-muscular mechanisms for future therapeutic interventions.
421 Further studies are needed to objectively measure altered sensory-motor reflex loops and axonal
422 damage in prodromal and early-to-moderate SPG4 subjects, e.g., a dynamometer-based H-reflex
423 measure and corticomuscular coherence measure, respectively.

424 **References**

- 425 **Bruel A**, Ghorbel SB, Russo AD, Stanev D, Armand S, Courtine G, Ijspeert A. Investigation of neural and biome-
426 chanical impairments leading to pathological toe and heel gaits using neuromusculoskeletal modelling. The
427 Journal of Physiology. 2022; n/a(n/a). doi: <https://doi.org/10.1113/JP282609>.
- 428 **De Groot F**, Falisse A. Perspective on musculoskeletal modelling and predictive simulations of human move-

- 429 ment to assess the neuromechanics of gait. *Proceedings of the Royal Society B: Biological Sciences*. 2021;
430 288(1946):20202432. doi: <https://doi.org/10.1098/rspb.2020.2432>.
- 431 **Delp SL**, Anderson FC, Arnold AS, Loan P, Habib A, John CT, Guendelman E, Thelen DG. OpenSim: Open-Source
432 Software to Create and Analyze Dynamic Simulations of Movement. *IEEE Transactions on Biomedical Engi-*
433 *neering*. 2007; 54(11):1940–1950. doi: <https://doi.org/10.1109/TBME.2007.901024>.
- 434 **Di Russo A**, Stanev D, Armand S, Ijspeert A. Sensory modulation of gait characteristics in human locomotion: A
435 neuromusculoskeletal modeling study. *PLOS Computational Biology*. 2021 05; 17(5):1–33. doi: [10.1371/jour-](https://doi.org/10.1371/journal.pcbi.1008594)
436 [nal.pcbi.1008594](https://doi.org/10.1371/journal.pcbi.1008594).
- 437 **Fink JK**. Hereditary spastic paraplegia. *Current neurology and neuroscience reports*. 2006; 6(1):65–76. doi:
438 <https://doi.org/10.1007/s11910-996-0011-1>.
- 439 **Fink JK**. Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. *Acta*
440 *neuropathologica*. 2013; 126(3):307–328. doi: <https://doi.org/10.1007/s00401-013-1115-8>.
- 441 **Geijtenbeek T**. SCONE: Open Source Software for Predictive Simulation of Biological Motion. *Journal of Open*
442 *Source Software*. 2019; 4(38):1421. doi: <https://doi.org/10.21105/joss.01421>.
- 443 **Geijtenbeek T**, The Hyfydy Simulation Software; 2021. <https://hyfydy.com>, <https://hyfydy.com>.
- 444 **Geyer H**, Herr H. A Muscle-Reflex Model That Encodes Principles of Legged Mechanics Produces Human Walk-
445 ing Dynamics and Muscle Activities. *IEEE Transactions on Neural Systems and Rehabilitation Engineering*.
446 2010; 18(3):263–273. doi: [10.1109/TNSRE.2010.2047592](https://doi.org/10.1109/TNSRE.2010.2047592).
- 447 **Globas C**, du Montcel ST, Baliko L, Boesch S, Depondt C, DiDonato S, Durr A, Filla A, Klockgether T, Mariotti C,
448 Melegh B, Rakowicz M, Ribai P, Rola R, Schmitz-Hubsch T, Szymanski S, Timmann D, Van de Warrenburg BP,
449 Bauer P, Schols L. Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. *Movement Disorders*. 2008;
450 23(15):2232–2238. doi: <https://doi.org/10.1002/mds.22288>.
- 451 **Haeufle DFB**, Schmorte B, Geyer H, Müller R, Schmitt S. The Benefit of Combining Neuronal Feed-
452 back and Feed-Forward Control for Robustness in Step Down Perturbations of Simulated Human Walk-
453 ing Depends on the Muscle Function. *Frontiers in Computational Neuroscience*. 2018; 12. doi:
454 <https://doi.org/10.3389/fncom.2018.00080>.
- 455 **Harding AE**. CLASSIFICATION OF THE HEREDITARY ATAXIAS AND PARAPLEGIAS. *The Lancet*. 1983;
456 321(8334):1151–1155. doi: [https://doi.org/10.1016/S0140-6736\(83\)92879-9](https://doi.org/10.1016/S0140-6736(83)92879-9), originally published as Volume
457 1, Issue 8334.
- 458 **Hazan J**, Fonknechten N, Mavel D, Paternotte C, Samson D, Artiguenave F, Davoine CS, Cruaud C, Dürr A,
459 Wincker P, et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant
460 spastic paraplegia. *Nature genetics*. 1999; 23(3):296–303. doi: <https://doi.org/10.1038/15472>.
- 461 **Igel C**, Suttorp T, Hansen N. A Computational Efficient Covariance Matrix Update and a (1+1)-CMA for
462 Evolution Strategies. In: *Proceedings of the 8th Annual Conference on Genetic and Evolutionary Compu-*
463 *tation GECCO '06*, New York, NY, USA: Association for Computing Machinery; 2006. p. 453–460. doi:
464 <https://doi.org/10.1145/1143997.1144082>.
- 465 **Ilg W**, Fleszar Z, Schatton C, Hengel H, Harmuth F, Bauer P, Timmann D, Giese M, Schöls L, Synofzik M. Individual
466 changes in preclinical spinocerebellar ataxia identified via increased motor complexity. *Movement Disorders*.
467 2016; 31(12):1891–1900. doi: <https://doi.org/10.1002/mds.26835>.
- 468 **Jansen K**, De Groote F, Aerts W, De Schutter J, Duysens J, Jonkers I. Altering length and velocity feedback during
469 a neuro-musculoskeletal simulation of normal gait contributes to hemiparetic gait characteristics. *Journal of*
470 *neuroengineering and rehabilitation*. 2014; 11(1):1–15. doi: <https://doi.org/10.1186/1743-0003-11-78>.
- 471 **van der Krogt MM**, Doorenbosch CA, Becher J, Harlaar J. Dynamic spasticity of plantar flexor muscles in cerebral
472 palsy gait. *Journal of rehabilitation medicine*. 2010; 42(7):656–663. doi: [https://doi.org/10.2340/16501977-](https://doi.org/10.2340/16501977-0579)
473 [0579](https://doi.org/10.2340/16501977-0579).
- 474 **van der Krogt MM**, Bar-On L, Kindt T, Desloovere K, Harlaar J. Neuro-musculoskeletal simulation of instru-
475 mented contracture and spasticity assessment in children with cerebral palsy. *Journal of NeuroEngineering*
476 *and Rehabilitation*. 2016; 13(1):1–11. doi: <https://doi.org/10.1186/s12984-016-0170-5>.

- 477 **Lassmann C**, Ilg W, Schneider M, Völker M, Haeufle DFB, Schüle R, Giese M, Synofzik M, Schöls L, Rattay TW. Specific gait changes in prodromal hereditary spastic paraplegia type 4 - preSPG4 study. *Movement Disorders*. 2022; doi: <https://doi.org/10.1002/mds.29199>.
- 480 **Lindig T**, Bender B, Hauser TK, Mang S, Schweikardt D, Klose U, Karle KN, Schüle R, Schöls L, Rattay TW. Gray and white matter alterations in hereditary spastic paraplegia type SPG4 and clinical correlations. *Journal of neurology*. 2015; 262(8):1961–1971. doi: <https://doi.org/10.1007/s00415-015-7791-7>.
- 483 **Marsden J**, Ramdharry G, Stevenson V, Thompson A. Muscle paresis and passive stiffness: Key determinants in limiting function in Hereditary and Sporadic Spastic Paraparesis. *Gait & Posture*. 2012; 35(2):266–271. doi: <https://doi.org/10.1016/j.gaitpost.2011.09.018>.
- 486 **Martino G**, Ivanenko Y, Serrao M, Ranavolo A, Draicchio F, Casali C, Lacquaniti F. Locomotor coordination in patients with Hereditary Spastic Paraplegia. *Journal of Electromyography and Kinesiology*. 2019; 45:61–69. doi: <https://doi.org/10.1016/j.jelekin.2019.02.006>.
- 489 **Martino G**, Ivanenko Y, Serrao M, Ranavolo A, Draicchio F, Rinaldi M, Casali C, Lacquaniti F. Differential changes in the spinal segmental locomotor output in Hereditary Spastic Paraplegia. *Clinical Neurophysiology*. 2018; 129(3):516–525. doi: <https://doi.org/10.1016/j.clinph.2017.11.028>.
- 492 **Millard M**, Uchida T, Seth A, Delp SL. Flexing Computational Muscle: Modeling and Simulation of Musculotendon Dynamics. *Journal of Biomechanical Engineering*. 2013 02; 135(2). doi: <https://doi.org/10.1115/1.4023390>, 021005.
- 495 **Mirelman A**, Bernad-Elazari H, Thaler A, Giladi-Yacobi E, Gurevich T, Gana-Weisz M, Saunders-Pullman R, Raymond D, Doan N, Bressman SB, Marder KS, Alcalay RN, Rao AK, Berg D, Brockmann K, Aasly J, Waro BJ, Tolosa E, Vilas D, Pont-Sunyer C, et al. Arm swing as a potential new prodromal marker of Parkinson's disease. *Movement Disorders*. 2016; 31(10):1527–1534. doi: <https://doi.org/10.1002/mds.26720>.
- 499 **Ong CF**, Geijtenbeek T, Hicks JL, Delp SL. Predicting gait adaptations due to ankle plantarflexor muscle weakness and contracture using physics-based musculoskeletal simulations. *PLOS Computational Biology*. 2019 10; 15(10):1–27. doi: [10.1371/journal.pcbi.1006993](https://doi.org/10.1371/journal.pcbi.1006993).
- 502 **Piccinini L**, Cimolin V, D'Angelo MG, Turconi AC, Crivellini M, Galli M. 3D gait analysis in patients with hereditary spastic paraparesis and spastic diplegia: A kinematic, kinetic and EMG comparison. *European Journal of Paediatric Neurology*. 2011; 15(2):138–145. doi: <https://doi.org/10.1016/j.ejpn.2010.07.009>.
- 505 **Rattay TW**, Völker M, Rautenberg M, Kessler C, Wurster I, Winter N, Haack TB, Lindig T, Hengel H, Synofzik M, Schüle R, Martus P, Schöls L. The prodromal phase of hereditary spastic paraplegia type 4: the preSPG4 cohort study. *Brain*. 2022 04; doi: <https://doi.org/10.1093/brain/awac155>, awac155.
- 508 **Rezende TJ**, de Albuquerque M, Lamas GM, Martinez AR, Campos BM, Casseb RF, Silva CB, Branco LM, D'Abreu A, Lopes-Cendes I, et al. Multimodal MRI-based study in patients with SPG4 mutations. *PLoS One*. 2015; 10(2):e0117666. doi: <https://doi.org/10.1371/journal.pone.0117666>.
- 511 **Rinaldi M**, Ranavolo A, Conforto S, Martino G, Draicchio F, Conte C, Varrecchia T, Bini F, Casali C, Pierelli F, Serrao M. Increased lower limb muscle coactivation reduces gait performance and increases metabolic cost in patients with hereditary spastic paraparesis. *Clinical Biomechanics*. 2017; 48:63–72. doi: <https://doi.org/10.1016/j.clinbiomech.2017.07.013>.
- 515 **Schreff L**, Haeufle DF, Vielemeyer J, Müller R. Evaluating anticipatory control strategies for their capability to cope with step-down perturbations in computer simulations of human walking. *Scientific reports*. 2022; 12(1):1–11. doi: <https://doi.org/10.1038/s41598-022-14040-0>.
- 518 **Schüle R**, Holland-Letz T, Klimpe S, Kassubek J, Klopstock T, Mall V, Otto S, Winner B, Schöls L. The Spastic Paraplegia Rating Scale (SPRS). *Neurology*. 2006; 67(3):430–434. doi: [10.1212/01.wnl.0000228242.53336.90](https://doi.org/10.1212/01.wnl.0000228242.53336.90).
- 520 **Serrao M**, Rinaldi M, Ranavolo A, Lacquaniti F, Martino G, Leonardi L, Conte C, Varrecchia T, Draicchio F, Coppola G, Casali C, Pierelli F. Gait Patterns in Patients with Hereditary Spastic Paraparesis. *PLOS ONE*. 2016 10; 11(10):1–16. doi: [10.1371/journal.pone.0164623](https://doi.org/10.1371/journal.pone.0164623).
- 523 **Song S**, Geyer H. A neural circuitry that emphasizes spinal feedback generates diverse behaviours of human locomotion. *The Journal of physiology*. 2015; 593(16):3493–3511. doi: <https://doi.org/10.1113/jp270228>.
- 525 **Van Lith BJ**, den Boer J, van de Warrenburg BP, Weerdsteijn V, Geurts A. Functional effects of botulinum toxin type A in the hip adductors and subsequent stretching in patients with hereditary spastic paraplegia. *Journal of Rehabilitation Medicine*. 2019; 51. doi: <https://doi.org/10.2340/16501977-2556>.

528 **Veerkamp K**, Waterval NFJ, Geijtenbeek T, Carty CP, Lloyd DG, Harlaar J, van der Krogt MM. Evaluat-
529 ing cost function criteria in predicting healthy gait. *Journal of Biomechanics*. 2021; 123:110530. doi:
530 <https://doi.org/10.1016/j.jbiomech.2021.110530>.

531 **Wang JM**, Hamner SR, Delp SL, Koltun V. Optimizing Locomotion Controllers Using Biologically-Based Actuators
532 and Objectives. *ACM Trans Graph*. 2012 jul; 31(4). doi: <https://doi.org/10.1145/2185520.2185521>.

533 **Waterval NFJ**, Veerkamp K, Geijtenbeek T, Harlaar J, Nollet F, Brehm MA, van der Krogt MM. Validation of
534 forward simulations to predict the effects of bilateral plantarflexor weakness on gait. *Gait & Posture*. 2021;
535 87:33–42. doi: <https://doi.org/10.1016/j.gaitpost.2021.04.020>.

536 **Data Availability**

537 The datasets for this manuscript are not publicly available because raw data regarding human
538 subjects (e.g., genetic raw data, personal data) are not shared freely to protect the privacy of the
539 human subjects involved in this study; no consent for open sharing has been obtained. Requests
540 to access an anonymous data set and simulation data should be directed to Christian Lassmann.

541 **Competing interests**

542 C.L., T.W.R, M.G., and D.F.B.H. report no competing interest.

543 W.I. has received consultancy honoraria by Ionis Pharmaceuticals, unrelated to the submitted work.

544 L.S. has received consultancy fees from Vico Therapeutics, unrelated to the submitted work.

545 **Authors Contribution**

546 C.L. designed the work, acquired, analyzed, and interpreted the data, and wrote the manuscript.
547 W.I. interpreted the data, and wrote and revised the manuscript. T.W.R. interpreted the data and
548 revised the manuscript. L.S. interpreted the data and revised the manuscript. M.G. interpreted the
549 data and revised the manuscript. D.F.B.H. designed the work, interpreted the data, and wrote and
550 revised the manuscript.

551 All authors approved the final version of the manuscript and agreed to be accountable for all
552 aspects of the work in ensuring that questions related to the accuracy or integrity of any part of
553 the work are appropriately investigated and resolved. All persons designated as authors qualify
554 for authorship, and all those who qualify for authorship are listed.

555 **Funding**

556 No funding was received for this work.

557 **Acknowledgments**

558 This work was supported by the Forum Ge(h)n mit HSP and the Förderverein für HSP-Forschung e.V.
559 (grant to L.S. and T.W.R.). T.W.R. received funding from the University of Tübingen, medical faculty,
560 for the Clinician Scientist Program Grant: #386-0-0. L.S. is a member of the European Reference
561 Network for Rare Neurological Diseases, Project ID 739510.